Marco Angelo Burgio

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

Medicine, Oncology, Pharmacology +16

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Hossein Borghaei, Scott Gettinger, Everett E. Vokes et al. · Journal of Clinical Oncology · 2021 · 661 citations · Full text

Medicine, Oncology, Pharmacology +14

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

E.E. Vokes, Neal Ready, Enriqueta Felip et al. · Annals of Oncology · 2018 · 469 citations · Full text

Medicine, Oncology, Pharmacology +17

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam et al. · The Lancet Oncology · 2019 · 365 citations · Full text

Medicine, Oncology, Immuno-oncology Pharmacotherapy +7

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Leora Horn, Hossein Borghaei et al. · Journal of Clinical Oncology · 2015 · 147 citations

Medicine, Oncology, Pharmacotherapy +11